Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $110,601.81 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,653 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the sale, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Howard Horn also recently made the following trade(s):

• On Friday, May 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70.
• On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $20.97, for a total transaction of $98,202.51.
• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total transaction of $36,624.00.

Ultragenyx Pharmaceutical Trading Up 2.9%

Shares of NASDAQ:RARE opened at $22.41 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37. The company’s 50 day moving average is $23.56 and its two-hundred day moving average is $25.55. The company has a market cap of $2.21 billion, a PE ratio of -3.67 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. During the same quarter in the previous year, the company posted ($1.57) EPS. The company’s quarterly revenue was down 2.2% on a year-over-year basis. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the business. Assetmark Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the period. Huntington National Bank boosted its stake in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Parallel Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares during the period. Leonteq Securities AG lifted its stake in shares of Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $39,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RARE. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. HC Wainwright lowered their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Barclays lowered their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Finally, Wall Street Zen cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.56.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.